ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
For patients with R/R MULTIPLE MYELOMA
ABECMA® reached its primary endpoint (≥PR as assessed by an IRC†) with an ORR of 72% (n=72/100) in the KarMMa pivotal study. Median time to onset for CRS was 1 day (range: 1 to 23 days), with a median duration of 7 days post infusion (range: 1 to 63 days). Median time to onset for NT was 2 days (range: 1 to 42 days), with a median duration of 5‡ days (range: 1 to 61 days) in 33 of 36 patients who had a resolved NT.1,2 See study design.
ABECMA is a BCMA-directed therapy studied in a broad patient population1
Identify your ABECMA-eligible patients and understand the ABECMA process
Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.
Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.
For patients who experienced NT, including 3 patients with ongoing NT, the median duration of CAR T cell-associated NT was 6 days (range: 1 to 578 days).
BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IRC=Independent Response committee; NT=neurologic toxicity; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory.
For patients with R/R MULTIPLE MYELOMA
ABECMA® reached its primary endpoint (≥PR as assessed by an IRC†) with an ORR of 72% (n=72/100) in the KarMMa pivotal study. Median time to onset for CRS was 1 day (range: 1 to 23 days), with a median duration of 7 days post infusion (range: 1 to 63 days). Median time to onset for NT was 2 days (range: 1 to 42 days), with a median duration of 5‡ days (range: 1 to 61 days) in 33 of 36 patients who had a resolved NT.1,2 See study design.
ABECMA is a BCMA-directed therapy studied in a broad patient population1
Identify your ABECMA-eligible patients and understand the ABECMA process
Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.
Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.
For patients who experienced NT, including 3 patients with ongoing NT, the median duration of CAR T cell-associated NT was 6 days (range: 1 to 578 days).
BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IRC=Independent Response committee; NT=neurologic toxicity; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory.
References: 1. ABECMA [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2021. 2. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. [Protocol BB2121-MM-001]. N Engl J Med. 2021;384(8):1-1012.